Article
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
NEJM evidence - 1 Jul 2022
Bernard Elsa, Tuechler Heinz, Greenberg Peter L, Hasserjian Robert P, Arango Ossa Juan E, Nannya Yasuhito, Devlin Sean M, Creignou Maria, Pinel Philippe, Monnier Lily, Gundem Gunes, Medina-Martinez Juan S, Domenico Dylan, Jädersten Martin, Germing Ulrich, Sanz Guillermo, van de Loosdrecht Arjan A, Kosmider Olivier, Follo Matilde Y, Thol Felicitas, Zamora Lurdes, Pinheiro Ronald F, Pellagatti Andrea, Elias Harold K, Haase Detlef, Ganster Christina, Ades Lionel, Tobiasson Magnus, Palomo Laura, Della Porta Matteo Giovanni, Takaori-Kondo Akifumi, Ishikawa Takayuki, Chiba Shigeru, Kasahara Senji, Miyazaki Yasushi, Viale Agnes, Huberman Kety, Fenaux Pierre, Belickova Monika, Savona Michael R, Klimek Virginia M, Santos Fabio P S, Boultwood Jacqueline, Kotsianidis Ioannis, Santini Valeria, Solé Francesc, Platzbecker Uwe, Heuser Michael, Valent Peter, Ohyashiki Kazuma, Finelli Carlo, Voso Maria Teresa, Shih Lee-Yung, Fontenay Michaela, Jansen Joop H, Cervera José, Gattermann Norbert, Ebert Benjamin L, Bejar Rafael, Malcovati Luca, Cazzola Mario, Ogawa Seishi, Hellström-Lindberg Eva, Papaemmanuil Elli
Abstract excerpt
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are not yet used in the risk stratification of patients with MDS. METHODS: To develop a clinical-molecular prognostic model (IPSS-Molecular...
Read the complete abstract on PubMed